Top

Published in:

01-11-2015 | Original Article

Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: back to the roots?

Authors: Dr. med. Christoph Henkenberens, Dr. med. Daniela Meinecke, Dr. med. Stoll Michael, Prof. Dr. med. Michael Bremer, Univ. Prof. Dr. med. Hans Christiansen

Published in: Strahlentherapie und Onkologie | Issue 11/2015

Abstract

Background

Chemoradiation (CRT) is the standard of care in patients with node-positive (cN+) and node-negative (cN0) anal cancer. Depending on the tumor size (T-stage), total doses of 50–60 Gray (Gy) in daily fractions of 1.8–2.0 Gy are usually applied to the tumor site. Inguinal and iliac lymph nodes usually receive a dose of ≥ 45 Gy. Since 2010, our policy has been to apply a reduced total dose of 39.6 Gy to uninvolved nodal regions. This paper provides preliminary results of the efficacy and safety of this protocol.

Patients and methods

Overall, 30 patients with histologically confirmed and node-negative anal cancer were treated in our department from 2009–2014 with definitive CRT. Histology all cases showed squamous cell carcinoma. A total dose of 39.6 Gy [single dose (SD) 1.8 Gy] was delivered to the iliac/inguinal lymph nodes. The area of the primary tumor received 50–59.4 Gy, depending on the T-stage. In parallel with the irradiation, 5-fluorouracil (5-FU) at a dose of 1000 mg/m² was administered by continuous intravenous infusion over 24 h on days 1–4 and 29–32, and mitomycin C (MMC) at a dose of 10 mg/m² (maximum absolute dose 14 mg) was administered on days 1 and 29. The distribution of the tumor stages was as follows: T1, n = 8; T2, n = 17; T3 n = 3. Overall survival (OS), local control (LC) of the lymph nodes, colostomy-free survival (CFS), and acute and chronic toxicities were assessed.

Results

The median follow-up was 27.3 months (range 2.7–57.4 months). Three patients (10.0 %) died, 2 of cardiopulmonary diseases and one of liver failure, yielding a 3-year OS of 90.0 %. Two patients (6.7 %) relapsed early and received salvage colostomies, yielding a 3-year CFS of 93.3 %. No lymph node relapses were observed, giving a lymph node LC of 100 %. According to the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE V. 4.0), there were no grade IV gastrointestinal or genitourinary acute toxicities. Seven patients showed acute grade III perineal skin toxicity. Acute grade III groin skin toxicity was not observed.

Conclusion

Reducing the total irradiation dose to uninvolved nodal regions to 39.6 Gy in chemoradiation protocols for anal carcinoma was safe and effective, and a prospective evaluation in future clinical trials is warranted.

Johnson LG, Madeleine MM, Newcomer LM et al (2004) Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. Cancer 101:281–288CrossRefPubMed

Frisch M (2002) On the etiology of anal squamous carcinoma. Dan Med Bull 49:194–209PubMed

Daling JR, Madeleine MM, Johnson LG et al (2004) Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101:270–280CrossRefPubMed

o A (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 348:1049–1054. (No authors listed)

Flam M, John M, Pajak TF et al (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14:2527–2539PubMed

Glynne-Jones R, Lim F (2011) Anal cancer: an examination of radiotherapy strategies. Int J Radiat Oncol Biol Phys 79:1290–1301CrossRefPubMed

Kachnic LA, Winter K, Myerson RJ et al (2013) RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluoroucil and mitomycin-C for the reduction of acute morbidity in carcinoma oft he anal canal. Int J Radiat Oncol Biol Phys 86:27–33PubMedCentralCrossRefPubMed

Bartelink H, Roelofsen F, Eschwege F et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15:2040–2049PubMed

Nigro ND, Seydel HG, Considine B et al (1983) Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 51:1826–1829CrossRefPubMed

10.

James RD, Glynne-Jones R, Meadows HM et al (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous cell carcinoma of the anus (ACT II): a randomized, phase 3, open label, 2 × 2 factorial trial. Lancet Oncol 14:516–524CrossRefPubMed

11.

Blinde SE, Schasfoort R, Mens JW et al (2014) Inguinal lymph node recurrence in the untreated groin of patients with anal carcinoma. Dis Colon Rectum 57:578–584CrossRefPubMed

12.

Call JA, Haddock MG, Quevedo JF et al (2011) Intensity-modulated radiotherapy for squamous cell carcinoma of the anal cacnal: Efficacyof a low daily dose to clinically negative regions. Radiat Oncol 6:134. doi:10.1186/1748-717X-6-134PubMedCentralCrossRefPubMed

13.

Kachnic LA, Tsai HK, Coen JJ et al (2012) Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 82:153–158CrossRefPubMed

14.

Mai SK, Welzel G, Hermann B et al (2009) Can the radiation dose to CT enlarged but FDG-PET negative inguinal lymph nodes in anal cacner be reduced? Strahlenther Onkol 185:254–259CrossRefPubMed

15.

Janssen S, Glanzmann C, Bauerfeind P et al (2014) Clinical experience of SIB-IMRT in anal cancer and selective literature review. Radiat Oncol 9:199. doi:10.1186/1748-717X-9-199PubMedCentralCrossRefPubMed

16.

Provencher S, Oehler S, Lavertu S, Jolicoeur M et al (2010) Quality of life after split-course chemoradiation for anal canal carcinoma. Radiat Oncol 5:41. doi:10.1186/1748-717X-5-41PubMedCentralCrossRefPubMed

17.

Serup-Hansen E, Linnemann D, Skovrinder-Ruminski W et al (2014) Human papillovirus genotyping and p16 expression as prognostic factors for patients with americanJoint Committee on Cancer stages I to III carcinoma of the anal canal. J Clin Oncol 32:1812–1817CrossRefPubMed

18.

International Commission on Radiation Units and Measurements (icru) ICRU Report 62. Bethesda: ICRU; 1999. Prescribing, Recording and Reporting Photon Beam Therapy [supplement to ICRU Report 50]

19.

International Commission on Radiation Units and Measurements (2010) ICRU Report 83. prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). J ICRU 10:1 doi: 10.1093/jicru/ndq002

20.

http://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed on 16/03/2015

21.

Pavy JJ, Denekamp J, Letschert J et al (1995) EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys 31:1043–1091CrossRefPubMed

22.

Northover J, Glynne-Jones R, Sebaq-Montefiore D et al (2010) Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCR Anal Cancer Trial (ACT I). Br J Cancer 102:1123–1128PubMedCentralCrossRefPubMed

23.

Zilli T, Betz M, Bieri S et al (2013) Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control. Int J Radiat Oncol Biol Phys 87:60–66CrossRefPubMed

24.

De Bari B, Lestrade L, Pommier P et al (2015) Could concomitant Radio-Chemotherapy improve the outcomes of early-stage node negative anal cancer patients? A retrospective analysis of 122 patients. Cancer Invest 33:114–120CrossRefPubMed

25.

National Cancer Comprehensive Network (2015) Guideline anal carcinoma version 2. http://www.nccn.org/professionals/physician_gls/pdf/anal.pdf. Accessed 16 March 2015

26.

Ajani JA, Winter KA, Gunderson LL et al (2008) Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299:1914–1921CrossRefPubMed

27.

Gerard JP, Chapet O, Samjei F et al (2001) Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of literature. Cancer 92:77–84CrossRefPubMed

28.

Grabenbauer GG, Kessler H, Matzel KE et al (2005) Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Dis Colon Rectum 48:1742–1751CrossRefPubMed

29.

Matthews JH, Burmeister BH, Borg M et al (2011) T1–2 anal carcinoma requires elective inguinal radiation treatment-the results of Trans-Tasman Radiation Oncology Group study TROG 99.02. Radiother Oncol 98:93–98CrossRefPubMed

30.

Peiffert D, Tournier-Rangeard L, Gérard JP et al (2012) Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal carcinoma: final analysis of the radomizes UNICANCER ACCORD 03 trial. J Clin Oncol 30:1941–1948CrossRefPubMed

31.

Wright JL, Patil SM, Temple LK et al (2010) Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. J Radiat Oncol Biol Phys 78:1064–1072CrossRef

32.

Glynne-Jones R, Kadalayil L, Meadows HM et al (2014) Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial. Ann Oncol 25:1616–1622CrossRefPubMed

33.

Fakhrian K, Sauer T, Dinkel A et al (2013) Chronic adverse events and quality of life after radiochemotherapy in anal cancer patients. A single institution experience and review of the literature. Strahlenther Onkol 189:486–494CrossRefPubMed

34.

Han K, Cummings BJ, Lindsay P et al (2014) Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. Int J Radiat Oncol Biol Phys 90:587–594CrossRefPubMed

35.

Frenzel T, Krüll A (2015) The use of IMRT in Germany. Strahlenther Onkol. (in press). DOI: 10.1007/s00066-015-0832-4

36.

Hernando-Requejo O, López M, Cubillo A et al (2014) Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation. Strahlenther Onkol 190:515–520CrossRefPubMed

37.

Devisetty K, Salama JK, Schomas DA et al (2009) A multi-institutional acute gastrointestinal toxcicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol 93:298–301CrossRefPubMed

Title: Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: back to the roots?
Authors: Dr. med. Christoph Henkenberens
Dr. med. Daniela Meinecke
Dr. med. Stoll Michael
Prof. Dr. med. Michael Bremer
Univ. Prof. Dr. med. Hans Christiansen
Publication date: 01-11-2015
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 11/2015
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-015-0885-4

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: back to the roots?

Abstract

Background

Patients and methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2015

Fertilitätserhalt bei Brustkrebs durch Embryo-Kryokonservierung nach ovarieller Stimulation mit Letrozol und FSH

Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma

Spatial oxygenation profiles in tumors during normo- and hyperbaric hyperoxia

Accelerating total body irradiation with large field modulated arc therapy in standard treatment rooms without additional equipment

Treatment of folliculitis decalvans using intensity-modulated radiation via tomotherapy

19th annual meeting of the scientific association of swiss radiation oncology (SASRO)